BR112018071395A2 - métodos de identificação de pacientes, método de previsão do risco de progressão para lvh, método de diferenciação em pacientes, métodos de previsão se pacientes se encontram com risco de progressão para lvh e uso - Google Patents

métodos de identificação de pacientes, método de previsão do risco de progressão para lvh, método de diferenciação em pacientes, métodos de previsão se pacientes se encontram com risco de progressão para lvh e uso

Info

Publication number
BR112018071395A2
BR112018071395A2 BR112018071395A BR112018071395A BR112018071395A2 BR 112018071395 A2 BR112018071395 A2 BR 112018071395A2 BR 112018071395 A BR112018071395 A BR 112018071395A BR 112018071395 A BR112018071395 A BR 112018071395A BR 112018071395 A2 BR112018071395 A2 BR 112018071395A2
Authority
BR
Brazil
Prior art keywords
lvh
progression
risk
patient
methods
Prior art date
Application number
BR112018071395A
Other languages
English (en)
Inventor
Ziegler André
Zaugg Christian
Block Dirk
Zannad Faiez
Rossignol Patrick
Wienhues-Thelen Ursula-Henrike
Original Assignee
Centre Dinvestigation Clinique Plurithematique Pierre Drouin Inserm Chu De Nancy Inst Lorrain Du Coe
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Dinvestigation Clinique Plurithematique Pierre Drouin Inserm Chu De Nancy Inst Lorrain Du Coe, Hoffmann La Roche filed Critical Centre Dinvestigation Clinique Plurithematique Pierre Drouin Inserm Chu De Nancy Inst Lorrain Du Coe
Publication of BR112018071395A2 publication Critical patent/BR112018071395A2/pt

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Abstract

a presente invenção refere-se a um método de identificação de pacientes que se encontram em risco de progressão para hipertrofia ventricular esquerda (lvh), que compreende as etapas de medição da quantidade do biomarcador st2 solúvel e comparação da quantidade medida desta forma com referência. são adicionalmente englobados pela presente invenção kits e dispositivos adaptados para conduzir o método de acordo com a presente invenção.
BR112018071395A 2016-04-18 2017-04-18 métodos de identificação de pacientes, método de previsão do risco de progressão para lvh, método de diferenciação em pacientes, métodos de previsão se pacientes se encontram com risco de progressão para lvh e uso BR112018071395A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16165776 2016-04-18
PCT/EP2017/059137 WO2017182446A1 (en) 2016-04-18 2017-04-18 Soluble st2 for the identification of progressors to lvh in the general population

Publications (1)

Publication Number Publication Date
BR112018071395A2 true BR112018071395A2 (pt) 2019-02-05

Family

ID=56014785

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018071395A BR112018071395A2 (pt) 2016-04-18 2017-04-18 métodos de identificação de pacientes, método de previsão do risco de progressão para lvh, método de diferenciação em pacientes, métodos de previsão se pacientes se encontram com risco de progressão para lvh e uso

Country Status (7)

Country Link
US (1) US20190279770A1 (pt)
EP (1) EP3446124A1 (pt)
JP (1) JP6983223B2 (pt)
KR (1) KR102112945B1 (pt)
CN (1) CN109863404A (pt)
BR (1) BR112018071395A2 (pt)
WO (1) WO2017182446A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2677611C1 (ru) * 2018-04-16 2019-01-17 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ прогнозирования неблагоприятных сердечно-сосудистых событий в течение 12 месяцев у больных хронической сердечной недостаточностью с рецидивом стенокардии после реваскуляризации миокарда
CN113588967B (zh) * 2021-08-03 2024-02-20 湖南永和阳光生物科技股份有限公司 一种生长刺激表达基因2蛋白的磁微粒化学发光检测试剂盒

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102533972B (zh) * 2002-05-09 2014-07-02 布赖汉姆妇女医院 作为心血管病的标志和治疗靶的1l1rl-1
WO2007130627A2 (en) * 2006-05-04 2007-11-15 The Brigham And Women's Hospital, Inc. Il-33 in the treatment and diagnosis of diseases and disorders
CN102498403B (zh) * 2009-09-17 2015-09-16 霍夫曼-拉罗奇有限公司 左心室肥大的多标记组
CN108387744A (zh) * 2010-08-26 2018-08-10 弗·哈夫曼-拉罗切有限公司 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途
CA2842072A1 (en) * 2011-07-18 2013-01-24 James V. Snider Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
US20130157290A1 (en) * 2011-12-16 2013-06-20 Yves Levy Soluble st2 as a marker for disease
WO2014031764A1 (en) * 2012-08-21 2014-02-27 Critical Care Diagnostics, Inc. Multimarker risk stratification
US9841430B2 (en) * 2013-09-10 2017-12-12 University Of Massachusettes Fractional C-reactive protein (fracCRP) antibodies and assays
CN104865387A (zh) * 2015-05-20 2015-08-26 瑞莱生物科技（江苏）有限公司 快速定量检测ST2和NT-proBNP的免疫荧光试纸条及其制备方法

Also Published As

Publication number Publication date
CN109863404A (zh) 2019-06-07
KR102112945B1 (ko) 2020-05-19
KR20190019919A (ko) 2019-02-27
JP6983223B2 (ja) 2021-12-17
US20190279770A1 (en) 2019-09-12
EP3446124A1 (en) 2019-02-27
JP2019514026A (ja) 2019-05-30
WO2017182446A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
WO2014201516A3 (en) Biomarker identification
BR112018069849A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático
BR112016029521A2 (pt) ?kit, dispositivo e método para a detecção de câncer de estômago?
BR112017009159A2 (pt) métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40
BR112014031365A2 (pt) métodos de detectar doenças ou condições
BR112018017168A2 (pt) emplastro de coloração do sangue, método e dispositivo para teste sanguíneo usando o mesmo
BR112016002845A2 (pt) composições e métodos para tratar condições associadas ao complemento
WO2015131151A3 (en) Method and apparatus for determining markers of health by analysis of blood
BR112015025407A2 (pt) método e dispositivo para testar um transformador
BR112013006764A2 (pt) método para avaliar um paciente, kit, meio legível por computador, método para avaliar um tratamento, método para avaliar o risco de um paciente, método para monitorar, método de diagnosticar, sistema de teste, método para classificar ou agrupar uma população de indivíduos, método para avaliar um desfecho substituto, método para tratar, uso de pelo menos um biomarcador, uso de um agente
BR112016019740A2 (pt) monitoramento do estado de inflamação
BR112014029233A8 (pt) método para diagnosticar se um indivíduo grávido não está em risco, usos de pelo menos um dos biomarcadores sfit-1, endoglina e pigf, dispositivo, kit, método de gestão de um indivíduo, sistema e método para estabelecer um auxílio
WO2017050939A3 (en) Method and array for diagnosing pancreatic cancer in an individual
BR112016002668A2 (pt) métodos e kits para prognosticar o risco de ter uma doença ou evento cardiovasculares
EP3605095A4 (en) KIT, METHOD AND REAGENT FOR MEASURING A SUBSTANCE MEASURED
BR112018073214A2 (pt) métodos para a previsão do risco de recorrência da fibrilação atrial, para o diagnóstico de fibrilação atrial em um indivíduo, para o monitoramento de uma terapia e para a classificação da fibrilação e utilizações do biomarcador
BR112018008799A2 (pt) método de prognóstico
BR112017011026A2 (pt) métodos analíticos e arranjos para uso nos mesmos
EP3605091A4 (en) KIT, METHOD AND REAGENT FOR MEASURING A SUBSTANCE MEASURED
BR112016024730A2 (pt) dispositivo, método e conjunto de análise imunocromatográfica
PE20180930A1 (es) Composiciones y metodos para la vigilancia activa del cancer de prostata
BR112015021666A2 (pt) Método implantado por computador para atualizar uma estimativa para uma propriedade de material de um volume e sistema de computador para atualizar uma estimativa para uma propriedade de material de um volume
BR112018067990A2 (pt) cromogranina a como um marcador para câncer de bexiga
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
BR112018071395A2 (pt) métodos de identificação de pacientes, método de previsão do risco de progressão para lvh, método de diferenciação em pacientes, métodos de previsão se pacientes se encontram com risco de progressão para lvh e uso

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements